Skip to main content

Results in Context: Nilotinib in Parkinson’s Disease (NILO-PD)

December 17, 2019

The cancer drug nilotinib repurposed for Parkinson's disease has been closely watched by the patient community. The NILO-PD study -- led by Northwestern University and funded by The Michael J. Fox Foundation -- has found no clinically meaningful benefit or biological effect in people with Parkinson's disease. Join us to hear from members of the steering committee on the trial's design and top-line findings and to ask your questions.

Webinar Details


Tuesday, December 17, 2019


1 hr


12:00 pm ET
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.